Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr 15;10(8):1694.
doi: 10.3390/jcm10081694.

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis

Leonardo Frazzoni  1   2 , Usama Sikandar  2 , Flavio Metelli  2 , Sinan Sadalla  2 , Giuseppe Mazzella  2 , Franco Bazzoli  1   2 , Lorenzo Fuccio  1   2 , Francesco Azzaroli  1   2
Affiliations
Review

Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Therapy with Direct-Acting Antivirals. A Systematic Review and Meta-Analysis

Leonardo Frazzoni et al. J Clin Med. .

Abstract

Background: Hepatocellular carcinoma (HCC) is a major cause of morbidity and mortality among patients with cirrhosis. The risk of HCC recurrence after a complete response among patients treated with direct-acting antivirals (DAAs) has not been fully elucidated yet.

Aim: To assess the risk of HCC recurrence after DAA therapy for hepatitis C virus (HCV).

Methods: A systematic review across PubMed, Scopus and Scholar up to November 2020, including full-text studies that assessed the pattern of HCC recurrence after DAA therapy for HCV. Random-effect meta-analysis and univariable metaregression were applied to obtain pooled estimates for proportions and relative risk (RR) and variables influential for the outcome, respectively.

Results: Thirty-one studies with 2957 patients were included. Overall, 30% (CI, 26-34%) of the patients with a history of HCC experienced HCC recurrence after DAA therapy, at mean time intervals ranging from 4 to 21 months. This result increased when going from European studies (23%, CI, 17-28%) to US studies (34%, CI, 30-38%), to Egyptian studies (37%, CI, 27-47%), and to Asian studies (33%, CI, 27-40%). Sixty-eight percent (CI, 45-91%) of recurrent HCCs developed within 6 months of follow-up since DAA treatment, among the eight studies providing stratified data. Among the studies providing head-to-head comparisons, the HCC recurrence risk was significantly lower after DAA therapy than IFN (RR, 0.64; CI, 0.51-0.81), and after DAA therapy than no intervention (RR, 0.68; CI, 0.49-0.94).

Conclusions: The recurrence of HCC after DAA is not negligible, being higher soon after the end of treatment and among non-European countries. DAA therapy seems to reduce the risk of HCC recurrence compared to an IFN regimen and no intervention.

Keywords: direct-acting antivirals (DAAs); hepatitis C virus (HCV); hepatocellular carcinoma (HCC).

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest, either personal or financial, to declare by any of the authors.

Figures

Figure 1
Figure 1
Flow-chart describing the process of study selection.
Figure 2
Figure 2
Proportion of patients developing hepatocellular carcinoma recurrence following direct-acting antiviral therapy.
Figure 3
Figure 3
Recurrence rate for hepatocellular carcinoma stratified by time elapsed from direct-acting antiviral therapy. (A) Within 6 months; (B) Between 6 and 12 months.
Figure 4
Figure 4
Relative risk of developing recurrent hepatocellular carcinoma according to strategy. (A) Direct-acting antivirals vs. interferon; (B) Direct-acting antivirals vs. no intervention.
Figure 5
Figure 5
Funnel plot describing publication bias for the primary outcome.
See this image and copyright information in PMC

References

    1. El-Serag H.B. Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology. 2012;142:1264–1273.e1. doi: 10.1053/j.gastro.2011.12.061. - DOI - PMC - PubMed
    1. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J. Hepatol. 2018;69:182–236. doi: 10.1016/j.jhep.2018.03.019. - DOI - PubMed
    1. Reddy S.K., Steel J.L., Chen H.-W., DeMateo D.J., Cardinal J., Behari J., Humar A., Marsh J.W., Geller D.A., Tsung A. Outcomes of Curative Treatment for Hepatocellular Cancer in Nonalcoholic Steatohepatitis versus Hepatitis C and Alcoholic Liver Disease. Hepatology. 2012;55:1809–1819. doi: 10.1002/hep.25536. - DOI - PubMed
    1. Holmes J.A., Rutledge S.M., Chung R.T. Direct-Acting Antiviral Treatment for Hepatitis C. Lancet. 2019;393:1392–1394. doi: 10.1016/S0140-6736(18)32326-2. - DOI - PubMed
    1. Singal A.G., Volk M.L., Jensen D., Di Bisceglie A.M., Schoenfeld P.S. A Sustained Viral Response Is Associated with Reduced Liver-Related Morbidity and Mortality in Patients with Hepatitis C Virus. Clin. Gastroenterol. Hepatol. 2010;8:280–288.e1. doi: 10.1016/j.cgh.2009.11.018. - DOI - PubMed

LinkOut - more resources